Dyslipidemias

Dyslipidemias | Internal Medicine

How it begins

Alteraciones del metabolismo lipídico: fundamentos moleculares, fisiopatología cardiovascular, clasificación nosológica y estrategias terapéuticas basadas en evidencia.

What it covers

1. Dyslipidemias
2. Definition, Classification and Epidemiology
3. · 1.1 · Etiological classification
4. · 1.2 · Fredrickson-WHO phenotypic classification
5. · 1.3 · Global and Latin American epidemiology
6. Biochemistry of Plasma Lipids
7. · 2.1 · Classes of plasma lipids
8. · 2.2 · Apolipoproteins: structure and function
9. · 2.3 · Structure of lipoproteins
10. Lipoprotein Metabolism
11. · 3.1 · Exogenous route (intestinal)
12. · 3.2 · Endogenous route (hepatic)
13. · 3.3 · Reverse cholesterol transport (CRT)
14. · 3.4 · Key enzymes and proteins of lipid metabolism
15. Receivers, Signaling and Regulation
16. · 4.1 · The LDL receptor (LDLR) and the Brown & Goldstein cycle
17. · 4.2 · The SREBP-2 / SCAP / Insig axis: master control of cholesterol
18. · 4.3 · LXR and FXR: other nuclear regulators
19. Primary Dyslipidemias
20. · 5.1 · Familial Hypercholesterolemia (FH)
21. · 5.2 · Familial Combined Hyperlipidemia (HFCom)
22. · 5.3 · Familial Dysbetalipoproteinemia (Fredrickson Type III)
23. · 5.4 · Severe Familial Hypertriglyceridemia and Familial Hyperchylomicronemia
24. · 5.5 · Dyslipidemias with low HDL
25. Secondary Dyslipidemias
26. Atherogenesis and Cardiovascular Risk
27. · 7.1 · LDL as a causal agent of atherosclerosis
28. · 7.2 · Concept of "accumulated LDL load"
29. · 7.3 · Other atherogenic lipid factors
30. · 7.4 · HDL-C: risk factor or marker?
31. Clinical Manifestations
32. · 8.1 · Skin and tissue manifestations
33. · 8.2 · Target organ manifestations: atherosclerotic complications
34. Diagnostic Evaluation
35. · 9.1 · The lipid profile: fasting or not fasting?
36. · 9.2 · LDL-C calculation
37. · 9.3 · Reference values and treatment thresholds
38. · 9.4 · Complementary studies
39. Cardiovascular Risk Stratification
40. · 10.1 · ESC/EAS risk categories 2019
41. · 10.2 · Additional risk modifiers (ESC/EAS 2019)
42. · 10.3 · Special very high risk groups
43. Non-Pharmacological Intervention
44. · 11.1 · Therapeutic diet
45. · 11.2 · Dietary patterns with evidence
46. · 11.3 · Physical exercise
47. · 11.4 · Other modifiable factors
48. Pharmacotherapy of Dyslipidemias
49. · 12.1 · Statins (HMG-CoA reductase inhibitors)
50. · 12.2 · Ezetimibe
51. · 12.3 · PCSK9 inhibitors (iPCSK9)
52. · 12.4 · Fibrates
53. · 12.5 · ω-3 fatty acids at pharmacological doses
54. · 12.6 · Bile acid sequestrants (resins)
55. · 12.7 · Niacin (nicotinic acid)
56. · 12.8 · New emerging therapies
57. · 12.9 · Combination therapy: principles
58. Special Clinical Cases
59. · 13.1 · Dyslipidemia in the elderly
60. · 13.2 · Dyslipidemia in pregnancy and lactation
61. · 13.3 · Dyslipidemia in diabetes mellitus
62. · 13.4 · Dyslipidemia in chronic kidney disease
63. · 13.5 · Dyslipidemia in HIV
64. · 13.6 · Intolerance to statins
65. Monitoring, Follow-up and Perspectives
66. · 14.1 · Step treatment algorithm
67. · 14.2 · Monitoring of lipid profile and safety
68. · 14.3 · Adherence to treatment: the biggest obstacle
69. · 14.4 · Screening in special populations
70. · 14.5 · Future perspectives in the treatment of dyslipidemias
71. · 14.6 · Summary of key points for the clinician